CXCR2-IN-1;CXCR2 inhibitor 1;Urea, N-(2-chloro-3-fluorophenyl)-N'-[4-chloro-2-hydroxy-3-[(1-methyl-4-piperidinyl)sulfonyl]phenyl]-;N-(2-Chloro-3-fluorophenyl)-N'-[4-chloro-2-hydroxy-3-[(1-methyl-4-piperidinyl)sulfonyl]phenyl]urea;CXCR-2-IN-1,CXCR2 IN 1,CXCR2IN1;CXCR2-IN-1, 10 mM in DMSO
CXCR2-IN-1 is a CNS-penetrant CXCR2 antagonist (pIC50 = 9.3) that demonstrates efficacy in a cuprizone-induced demyelination model upon oral administration, supporting CXCR2 as a potential therapeutic target for treating demyelinating diseases such as multiple sclerosis.